menu

CARE HK in HF: Designing a Real-world Study to Identify Barriers to Guideline-directed RAASi Therapy

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

CARE HK in HF: Designing a Real-world Study to Identify Barriers to Guideline-directed RAASi Therapy

close
CARE HK in HF: Designing a Real-world Study to Identify Barriers to Guideline-directed RAASi Therapy
Restart
Resume
Read full article
Choose a format
Media formats available:
Details
Presenters
Related
Comments
  • Sponsored by

  • Overview

    Despite evidence and guideline recommendations, renin-angiotensin-aldosterone system inhibitor (RAASi) therapy tends to be used suboptimally among patients with heart failure (HF), particularly in patients with chronic kidney disease (CKD). What are the real-world factors that influence RAASi treatment decisions in patients with HF who have or are at risk for hyperkalemia? Hear about how the CARE HK in HF study is being designed to explore the real-world data surrounding this question and its associated impact on outcomes.

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Sponsored by

  • Overview

    Despite evidence and guideline recommendations, renin-angiotensin-aldosterone system inhibitor (RAASi) therapy tends to be used suboptimally among patients with heart failure (HF), particularly in patients with chronic kidney disease (CKD). What are the real-world factors that influence RAASi treatment decisions in patients with HF who have or are at risk for hyperkalemia? Hear about how the CARE HK in HF study is being designed to explore the real-world data surrounding this question and its associated impact on outcomes.

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 11/28/20